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Oncogene and Growth Factor Expression in MEN 2 and Related
Tumors

Jeffrey F. Moley,* Goran K. Wallin,* Michele B. Brother,* Michael Kim,* Samuel A.
Wells, Jr,* and Garrett M. Brodeur^

Pheochromocytomas occur sporadically or in individuals aff'ected by inherited syndromes including
multiple endocrine neoplasia (MEN) type 2A and 2B, neurofibromatosis, and the von Hippel-Lindau
syndrome (vHL). Medullaiy thyroid carcinomas (MTCs) also occur sporadically or as part of MEN
2A, MEN 2B, andfamilial MTC. Little is known ofthe molecular genetic background ofthese tumors.
We have shown previously that activation ofthe N-ras, //-ras, and K-ras oncogenes does not occur in
these tumors, but that deletions ofthe short arm of chromosome 1 are extremely common (> 60%) and
may indicate loss ofa suppressor gene in the chromosomal region lp31-36. We have examined the
structure and expression of N-myc, c-myc, L-myc, c-mos, nerve growth factor (^-NCF), and the low
affinity nerve growth factor receptor (LNGFR) in a series of pheochromocytomas and MTCs ft-om
patients with hereditary and sporadic diseases. Southern analysis, using radiolabeled DNA probes,
revealed no evidence of amplification or rearrangement ofthese genes in any normal or tumor tissues
except for loss of heterozygosity at the L-myc locus (lp32) in 9 pheochromocytomas from patients
with MEN 2A or MEN 2B, in 5 of 11 non-MEN pheochromocytomas, and in 3 of 24 non-MEN MTCs.
Gene expression at the RNA level was examined by Northern analysis or ribonuclease protection
assay (RPA) using radiolabeled DNA or cRNA probes. C-myc transcripts were detectable at low
levels in all tumors tested. L-myc and c-mos transcripts were not detectable'inany tumor, and N-myc
transcripts were detectable at low levels in all tumors by Northern analysis or RPA. LNGFR transcripts were not detectable in four tumors (tn'o vHL pheochromocytomas, /vi'c) sporadic pheochromocytomas). but were present at low levels in all other tumors. High levels of gene transcripts, or
abnormally sized transcripts, were not seen in any tumor. Deletion of chromosome Ip remains the
most consistent and significant molecular genetic abnormality yet identified in these tumors. (Henry
Ford Hosp MedJ 1992:40:284-8]

M

edullary thyroid carcinomas (MTCs) and pheochromocytomas can occur sporadically or in patients with certain
familial predisposition syndromes. In multiple endocrine neoplasia (MEN) type 2A and type 2B, patients inherit a susceptibility to the development of MTCs and pheochromocytomas.
Familial MTC (FMTC) is another type of MTC which is inherited as an autosomal dominant trait in which patients develop
MTCs only. Pheochromocytomas also occur in patients with
von Hippel-Lindau (vHL) syndrome and neurofibromatosis
type 1. Genetic linkage studies have mapped the predisposing
gene in MEN 2A, MEN 2B, and FMTC to the pericentromeric
region of chromosome 10 (1-6); however, the predisposing
gene(s) has not yet been identified.
The molecular genetic events underlying tumor formation in
MEN 2A and MEN 2B are not understood. Unlike hereditary
retinoblastoma, deletion or loss of heterozygosity (LOH) in the
region of the predisposing locus is found rarely in pheochromocytomas and MTCs from these patients (7-9). It is possible
that malignant transformation in the MEN 2 syndromes is
caused by other mechanisms, such as oncogene activation and/
or the inactivation of a tumor suppressor gene at a different chromosomal locus. We and others have reported chromosome 1
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LOH in pheochromocytomas and MTCs from patients with
MEN 2A and MEN 2B (10-14), and it is possible that this region
harbors a tumor suppressor gene whose inactivation is important in tumorigenesis. Evidence of oncogene activation in these
tumors has not been found as yet. We examined ras gene sequences in sporadic and hereditary MTCs and pheochromocytomas and found no mutations or deletions (10,15). In this report,
we examine the oncogenes N-myc, c-myc, L-myc, artd C-mos,
nerve growth factor ((i-NGF), and the low affinity nerve growth
factor receptor (LNGFR) in MTCs and pheochromocytomas. N myc, c-myc, and L-myc were examined because they frequently
are amplified or overexpressed in other tumors of neural crest
origin (16-18). C-mos was examined because transgenic mice
which express the c-mos gene develop pheochromocytomas and
MTCs (19). LNGFR was examined because it is involved in the
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differentiation of a rat pheochromocytoma cell line, and because
abnormalities of this receptor have been noted at the DNA,
RNA, and protein levels in a closely related neural crest-derived
tumor, neuroblastoma (20,21).

SSC, and filters were then baked at 80 °C. Filters were prehybridized for several hours and then hybridized with purified
plasmid DNA inserts labeled by the random hexamer primer
technique (24). Filters were then washed and exposed to film for
one to three days.

Materials and Methods
Tumors and constitutional tissue were obtained at the time of
diagnostic or therapeutic surgery. Tumor specimens were frozen immediately in liquid nitrogen and subsequently thawed
only for preparation of DNA and RNA. These studies have been
approved by an institutional human studies committee.
DNA studies
We examined normal and tumor DNA from 18 patients with
pheochromocytomas (7 MEN 2A, 2 MEN 2B, 7 sporadic, 2
vHL) and 27 patients with MTCs (14 MEN 2A, 7 MEN 2B, 6
sporadic) for abnormalities of the N-myc, c-myc, and L-myc
genes. We exainined normal and tumor DNA from f f patients
with pheochromocytomas (5 MEN 2A, 1 MEN 2B, 5 .sporadic)
for abnormalities of the (S-NGF gene. The LNGFR gene was examined in normal and tumor DNA from 13 patients with pheochromocytomas (7 MEN 2A, 4 sporadic, 2 vHL), and 10 patients with MTCs (6 MEN 2A, 2 MEN 2B, 2 sporadic). The cmos gene was examined in normal and tumor DNA from 12 patients with pheochromocytomas (6 MEN 2A, 4 sporadic, 2
vHL), and five patients with MTCs (3 MEN 2A, 1 MEN 2B, 1
sporadic). DNA was prepared from tumors by standard detergent proteina.se K lysis followed by organic extraction and extensive dialysis. Following appropriate digestion, electrophoresis, and Southem transfer (22), fihers were hybridized
with plasmid probes or purified plasmid DNA inserts labeled by
the nick translation (23) or random hexamer primer (24) technique. For N-myc, c-myc, and L-myc, the DNA was digested
with Eco Rl; for |3-NGF, the DNA was digested with Bgl I I ;
and for c-mos, the DNA was digested with Bam H1.
RNA studies
We examined the proto-oncogenes N-myc, c-myc, L-myc, and
c-mos, and the LNGFR at the RNA level in pheocfiromocytomas and MTCs. N-myc expression was examined in 10 pheochromocytomas (3 MEN 2 A, 1 MEN 2B, 4 sporadic, 2 vHL) and
two MTCs (I MEN 2B and 1 sporadic). C-myc expression was
examined in four pheochromocytomas (2 MEN 2A, 2 sporadic,
and 2 MTCs [1 MEN 2B and 1 sporadic]). L-myc expression
was examined in 10 pheochromocytomas (3 MEN 2A, 1 MEN
2B, 4 sporadic, and 2 vHL) and one MTC (MEN 2B). C-mos expression was examined in nine pheochromocytomas (2 MEN
2A, I MEN 2B, 4 sporadic, and 2 vHL). LNGFR expression was
examined in 13 pheochromocytomas (3 MEN 2A, 2 MEN 2B, 6
sporadic, 2 vHL) and one MTC (MEN 2B). Total RNA preparation was done by the method of Chomzynski and Sacchi (25).
The size and amount of mRNA for N-myc, c-myc, L-myc, cmos, and LNGFR were analyzed by Northem analysis of total
cellular RNA. Thirty micrograms of RNA were denatured and
electrophoresed on a formaldehyde-containing 0.8% agarose
gel. The RNA was transferred to nitrocellulose filters in lOX
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Probes
For N-myc DNA and RNA studies, we used a full-length Nmyc cDNA which is subcloned into the plasmid vector,
Bluescript (Stratagene, San Diego, CA) (26). For c-myc, we
used a cDNA clone which was obtained from Dr. R. Eisenman
(27) . A genomic L-myc clone was obtained from Dr. J. Minna
(28) . For c-mos, we used a plasmid clone from Dr. G. Vande
Woude which contains the entire coding sequence (the gene has
a single 1.4 kb reading frame) (29). A full-length cDNA clone of
LNGF was obtained from Dr. M. Chao (30). The (3-NGF probe
was obtained from Dr. A. Ullrich (31). Controls using a p-actin
probe (32) were performed to demonstrate that expected
amounts of undergraded RNA were transferred to the filters.
Ribonuclease protection assays
Ribonuclease protection assays (RPAs) were done to look for
low-level expression of N-m>'c and c-mos. In these assays, portions of the N-myc and c-mos cDNAs were subcloned into
Bluescript (Strategene, San Diego, CA), a plasmid vector which
contains T3 and T7 RNA polymerase promoters flanking the restriction site polylinker, into which the cDNA fragments were
subcloned. Antisense cRNA fragments of specific size (200 to
300 base pairs) were then generated, incorporating -''^P UTP label. These fragments were mixed with the test DNA, and the solution was then treated with RNase to digest any single stranded
fragments. Aliquots were electrophoresed on denaturing acrylamide gels, which were then exposed to film.

Results
DNA studies
There was no evidence of deletion, amplification, or rearrangement of the N-myc, c-myc, L-myc, c-mos, |3-NGF, or
LNGFR genes in any tumor studied. For these probes, all tumors
demonstrated the expected normal band pattem and intensity.
However, LOH at the L-myc locus (lp32) (33) was identified in
9 pheochromocytomas in MEN 2A and MEN 2B patients, compared to only 2 of 7 sporadic pheochromocytomas. We also
found L-myc LOH in 1 of 2 vHL pheochromocytomas. L-myc
LOH was noted in 3 of 24 informative MTCs from patients with
MEN 2 A. LOH on chromosome 1 p has been reported by us previously (10,11). The (3-NGF locus also maps to the short arm of
chromosome 1; however, none of the 11 individuals studied
were informative, using two different probe-enzyme combinations previously reported to have a high percentage of informativeness (34).
RNA studies
Using Northem analysis, N-myc transcripts were detected in
6 of 10 pheochromocytomas (4 sporadic, 2 vHL) (Fig 1). These
transcripts were of expected size. Transcripts (Fig 1) were not
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Fig I—Northern analysis of tumor RNA. Autoradiogram of a
nitrocellulose filter containing total cellular RNA from cell
lines and tumor RNA, probed with radiolabeled N-myc cDNA
probe (top). L-myc probe (second from top), c-mos probe (third
from top], and ^-actin probe (bottom). For description of
probes, see text. KCN: neuroblastoma cell line which amplified
and overexpresses N-myc; NSH: neuroblastoma cell line which
does not amplify N-myc. 2-16: representative pheochromocytoma RNAs. 2,3,5,13; sporadic tumors. 10: MEN2A tumor. 15,
16: von Hippel-Lindau tumors. Normal-sized N-myc transcripts are present in tumors 2,3, and 5. No transcripts are seen
for N-myc in other tumor RNAs, and no expression was detected
for c-mos or L-myc in any tumor.
seen in one MEN 2B and three MEN 2A tumors. Using the ribonuclease protection assay, low levels of transcription of N-myc
were found to be present in all pheochromocytomas and MTCs
tested (Fig 2) including an MEN 2A pheochromocytoma (case
8) in which Northem analysis did not show expression, N-myc
expression was detected in two MTCs tested by ribonuclease
protection assay (one MEN 2B, one sporadic). C-myc expres-
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Fig 2—Ribonuclease protection assay for N-myc expression.
Total cellular RNA was incubated with radiolabeled N-myc antisense cRNA probe of defined length. Single-stranded RNA was
then digested with RNase, and the remaining protected doublestranded fragments electrophoresed on a denaturing 6% acrylamide gel, which was then expo,sedfor I hour. Arrow: location
ofprotectedft-agment, which is present in all tumor and cell line
lanes. KCN: neuroblastoma cell line which overexpresses Nmyc. NSH: neuroblastoma cell line which does not amplify Nmyc. PH2, 3, and 5: sporadic pheochromocytomas. PHS: MEN
2A pheochromocytoma. TH4: sporadic MTC. THS: MEN 2B
MTC.

sion was detected by Northem analysis in ad six tumors tested,
though at very low levels (data not shown). L-myc and c-mo^
transcripts were not detectable in any tumor by Northem analysis (Fig 1). Ribonuclease protection assay also failed to detect
any expression of c-mos in two tumors tested. LNGFR transcripts were not detectable in five tumors (1 MEN 2A, 2 MEN
2B, 2 sporadic pheochromocytomas), but were present in all
other tumors (Fig 3). High levels of gene transcripts were not
seen in any tumor (Fig 3).

Discussion
Because the predisposition gene for the MEN 2 syndromes in
the pericentromeric region of chromosome 10 has not been
cloned and characterized as yet, it is not possible to completely
rule out the possibility that inactivation of the normal inherited
allele results in tumor formation in these patients. However, re-
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cent reports have noted allelic loss on chromosome 10 in tumors
of only 4 of 86 informative cases (7-9). This contrasts with the
situation in hereditary retinoblastoma in which tumors that occur in predisposed individuals achieve homozygosity for a defective RB-1 allele in the majority of cases (35,36). It is possible
dial malignant transformation in the MEN 2 syndromes is
caused by other mechanisms, such as oncogene activation or the
inactivation ofa tumor suppressor gene at a different chromosomal locus.
The data presented here add to the growing body of information regarding the molecular biology of pheochromocytomas
and MTCs. We (15) and others (9) previously reported that ras
gene mutations do not occur in these tumors. Overexpression of
the proto-oncogene N-myc has been reported in 6 of 21 MTCs
analyzed by in situ hybridization (37), and a recent study demonstrated expression (without gene amplification or rearrangement) of c-myc and c-fos in six pheochromocytomas, suggesting
that these ceUs are in a state of growth stimulation (38). In this
study, we evaluated the possible role of the N-myc, c-myc, Lmyc, and c-mos genes in die development of these tumors and
have found no evidence that their activation plays a role. At
present, there is little evidence that oncogene activation plays a
role in the development of these tumors. This contrasts with
other related tumors of neural crest origin, such as neuroblastoma or melanoma, in which activation of specific oncogenes is
seen with substantial frequency (15,39,40).
The pattera of hyperplasia of selected target organs preceding
the development of overt neoplasia in the MEN 2 syndromes
suggests that abnormal regulation of growth and differentiation
may be important in the growth and development of these tumors. The NGFR pathway is required for the survival of sympathetic and sensory neurons and is known to cause differentiation
ofthe rat pheochromocytoma cell line PC 12 into cells resembling sympathetic neurons (41-43). There is evidence that the
NGFR pathway is critically important to the development and
differentiation of normal chromaffin cells, the cell of origin of
pheochromocytomas. Multiple defects in the NGFR pathway
have been described in neuroblastoma (21), a tumor which is
embryologically related to pheochromocytoma. In diis report,
we found no abnormalities of the P-NGF or LNGFR genes at the
DNA level, and we found absence of detectable expression of
LNGFR in the majority of pheochromocytomas tested. No evidence of abnormal expression, such as abnormal transcript size,
was noted; however, it is possible that the lack of expression of
this receptor may contribute to the maintenance ofthe undifferentiated state in pheochromocytomas and MTCs.
We have reported that deletion of the short arm of chromosome 1 occurs in all pheochromocytomas from patients with
MEN 2A and MEN 2B and in a substantial number of sporadic
tumors and MTCs (10,11). This is the most consistent abnormality so far described in tumors from patients with MEN 2A
and MEN 2B. The consistent finding of this deletion suggests
the presence of a tumor suppressor gene in this region. Deletion
ofthis gene may be the second "hit," which results in the development of pheochromocytomas in patients with MEN 2A and
MEN 2B, and may also contribute to the development of MTCs
m MEN 2A and of sporadic pheochromocytomas and MTCs.
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Fig 3~-Northern analysis of LNGFR expression. Autoradiogram of nitrocellulose filter containing total cellular RNA from
pheochromocytoma RNA probed with radiolabeled LNGFR cDNA probe (top) and radiolabeled ^-actin probe (bottom). Tumors I, 8, and 10: MEN2A pheochromocytomas. Tumors 2, 3,
5, 13A, and I3B: sporadic pheochromocytomas. Tumors IIA,
1 IB: MEN 2Bpheochromocytomas (A and B designate different
tumors from the same patient). Tumors I and 5 demonstrate
moderate expression of normal-sized LNGFR transcripts (3.8
kB). Tumors 2, 3, and 10 have low levels of LNGFR transcripts.
In tumors 8, llA and I IB. and I3A and I3B, no transcripts
were detectable.

Despite extensive studies by us (10,11,15) and others (9,37,
38), little evidence for activation of oncogenes or growth factors
has been found as yet in pheochromocytomas and MTCs. Deletions of chromosome lp remain the most consistent and significant molecular genetic abnormality yet identified in these tumors.
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